1 |
Goodman GE, Yen YP, Cox TC, Crowley J. 1987. Effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells. Cancer Res. 47: 2295-2304.
|
2 |
Ahn HJ, Kim JY, Lee CH, Song IS, Liu KH. 2008. Screening of chemosensitizer candidates using natural extracts. J. Life Sci. 9: 1244-1248.
|
3 |
Shen DW, Goldenberg S, P astan I, Gottesman MM. 2000. Decreased accumulation of [ ] carboplatin in human cisplatin-resistant cells results from reduced energy dependent uptake. J. Cell Physiol. 183: 108-116.
DOI
|
4 |
Goto S, Kamada K, Soh Y, Ihara Y, Kondo T. 2002. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn. J. Cancer Res. 93: 1047-1056.
DOI
|
5 |
Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. 2005. Hypoxia-induced dedifferentiation of tumor cells-A mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell DevBiol. 16: 554-563.
DOI
|
6 |
Brown JM, Giaccia AJ. 1998. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58: 1408-1416.
|
7 |
Tomida A, Tsuruo T. 1999. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des. 14: 169-177.
|
8 |
Acker T, Plate KH. 2002. A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. J. Mol. Med. 80: 562-575.
DOI
|
9 |
Vaupel P, Yhews O, Hoeckel M. 2001. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 18: 243-259.
DOI
|
10 |
Chen AY, Liu LF. 1994. Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat. Res. 73: 263-281.
DOI
|
11 |
Coux O, Tanaka, Goldberg AL. 1996. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65: 801-847.
DOI
|
12 |
Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, et al. 1994. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542.
DOI
|
13 |
Wang JC. 1996. DNA topoisomerases. Annu. Rev. Biochem. 65: 635-692.
DOI
|
14 |
Froelich-Ammon SJ, Osheroff N. 1995. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270: 21429-21432.
DOI
|
15 |
Ma Y, Hendershot LM. 2001. The unfolding tale of the unfolded protein pesponse. Cell 107: 827-830.
DOI
|
16 |
Mazzarella RA, Green M. 1987. Erp99, and abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to 90 kDa heat shock protein (hsp90) and the 94 kDa glucose-regulated protein (GRP94). J. Biol. Chem. 262: 74-108.
|
17 |
Choo SJ, Park HR, Ryoo IJ, Kim JP, Yun BS, Kim CJ, et al. 2005. Deoxyverrucosidin, a novel GRP78/BiP down-regulator, produced by Penicillium sp. J. Antibiot. 58: 210-213.
DOI
|
18 |
Yu JL, Coomber BL, Kerbel RS. 2002. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 70: 599-609.
DOI
|
19 |
Fernandez PM, Tabbara SO, Jacobs LK, Manning FCR, Tsangaris TN, Schwarts AM, et al. 2000. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res. Treat. 59: 15-26.
DOI
|
20 |
Umehara K, Nakamura M, Miyase T, Kuroyanagi M, Ueno A. 1996. Studies on differentiation inducers. VI. Lignan derivatives from Arctium fructus. (2). Chem. Pharm. Bull. 44: 2300-2304.
DOI
|
21 |
Zhao F, Wang L, Liu K. 2009. In vitro anti-inflammatory effects of arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. J. Ethnopharmacol. 122: 457-462.
DOI
|
22 |
Zhang N, Wen Q, Ren L, Liang W, Xia Y, Zhang X, et al. 2013. Neuroprotective effect of arctigenin via upregulation of P-CREB in mouse primary neurons and human SH-SY5Y neuroblastoma cells. Int. J. Mol. 14: 18657-18669.
DOI
|
23 |
Ogiso Y, Tomida A, Tsuruo T. 2002. Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs. Cancer Res. 62: 5008-5012.
|
24 |
Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. 2000. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 60: 2429-2434.
|